I’ve just received the following from Twitter:

The article in question was Efficacy of single-dose and double-dose ivermectin early treatment in preventing progression to hospitalization in mild COVID-19: A multi-arm, parallel-group randomized, double-blind, placebo-controlled trial. This is featured in Trip as ‘Key Primary Research’ as it has gone through additional layers of quality control via the wonderful EvidenceAlerts system. As they say on their site:

EvidenceAlerts is an Internet service that notifies physicians and researchers about newly-published clinical studies. Researchers at the McMaster Health Information Unit find the highest quality studies, reviews, and evidence-based clinical practice guidelines from 112 premier clinical journals and these articles are rated by practicing physicians for clinical relevance and interest. Alerts are curated to your own clinical interests.

Their rating for that particular paper (the banned one) can be seen here. The raters gave it this score:

The conclusion of the actual paper was:

Conclusion: Single-dose and double-dose ivermectin early treatment were not superior to the placebo in preventing progression to hospitalization and improving clinical course in mild COVID-19.

So, is the mis-information the claim that ivermectin is no better than placebo?

There is so much information out there on ivermectin e.g.:

We found no evidence to support the use of ivermectin for treating COVID-19 or preventing SARS-CoV-2 infection” (Cochrane)

Why You Should Not Use Ivermectin to Treat or Prevent COVID-19” (FDA)

The current evidence on the use of ivermectin to treat COVID-19 patients is inconclusive. Until more data is available, WHO recommends that the drug only be used within clinical trials” (WHO)

Do not use ivermectin to treat COVID-19 except as part of an ongoing clinical trial” (NICE)

This is appalling!

UPDATE: the ban was temporary and our account is now back!